Assessment of Baseline Clinical Predictive Factors of Response to Cetuximab-Irinotecan in Patients with Irinotecan-Refractory Metastatic Colorectal Cancer

Publisher： Karger

E-ISSN： 1423-0232|73|3-4|185-191

ISSN： 0030-2414

Source： Oncology, Vol.73, Iss.3-4, 2008-04, pp. : 185-191

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The Role of KRAS Mutations in Predicting the Efficacy of Cetuximab-Plus-Irinotecan Therapy in Irinotecan-Refractory Korean Metastatic Colorectal Cancer Patients

By  

Oncology, Vol. 77, Iss. 3-4, 2009-09 ,pp. : 224-230

Karger

Access to resources Recommend Favorite

Genetic Polymorphisms of FcγRIIa and FcγRIIIa Are Not Predictive of Clinical Outcomes after Cetuximab plus Irinotecan Chemotherapy in Patients with Metastatic Colorectal Cancer

By  

Oncology, Vol. 82, Iss. 2, 2012-02 ,pp. : 83-89

Karger

Access to resources Recommend Favorite

Phase II Trial of Cetuximab plus Irinotecan for Oxaliplatin- and Irinotecan-Based Chemotherapy-Refractory Patients with Advanced and/or Metastatic Colorectal Cancer: Evaluation of Efficacy and Safety Based on KRAS Mutation Status (T-CORE0801)

By  

Oncology, Vol. 87, Iss. 1, 2014-06 ,pp. : 7-20

Karger

Access to resources Recommend Favorite

Gefitinib in Combination with Oxaliplatin and 5-Fluorouracil in Irinotecan-Refractory Patients with Colorectal Cancer: A Phase I Study of the Arbeits gemeinschaft Internistische Onkologie (AIO)

By  

Oncology Research and Treatment, Vol. 31, Iss. 5, 2008-04 ,pp. : 237-241

Karger

Access to resources Recommend Favorite

Irinotecan and Mitomycin C in 5-Fluorouracil-Refractory Colorectal Cancer Patients

By  

Oncology, Vol. 60, Iss. 2, 2001-02 ,pp. : 127-133

Karger

Access to resources Recommend Favorite